Aging population, better survival drive projected rise in ALS cases
Because the global population is aging and people with amyotrophic lateral sclerosis (ALS) are living longer, the number of…
Articles by Steve Bryson, PhD
Enrollment complete in clinical trial of ALS drug MN-166
Patient enrollment is complete in a Phase 2b/3 clinical trial evaluating MN-166 (ibudilast), an investigational oral therapy developed by…
New study IDs better method to detect gene defects in sporadic ALS
Long-read DNA sequencing is a more accurate method than short-read sequencing for detecting certain defects in genes associated with an…
AP-101 holds promise for some with ALS, topline data show
AP-101, AL-S Pharma’s amyotrophic lateral sclerosis (ALS) therapy, was safe and well tolerated and led to clinically meaningful benefits…
ALS gene therapy prepares to move to clinical trials in China, US
China’s National Medical Products Administration has granted Sineugene Therapeutics permission to begin clinical trials of its gene therapy SNUG01…
Exposure to air pollutant sulfur dioxide tied to greater ALS risk
Long-term exposure to sulfur dioxide (SO2), a gaseous air pollutant generated by the burning of fossil fuels, significantly increases the…
FDA grants orphan drug status to ALS gene therapy SNUG01
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Sineugene Therapeutics‘ SNUG01, a gene therapy…
Living near toxic algal blooms tied to shorter survival in ALS patients
Living close to water bodies with blue-green algae blooms, or cyanobacteria, is linked to significantly reduced survival among people with…
Researchers discover cell pathway that prevents TDP-43 aggregation
Researchers have discovered a pathway in cells that prevents the formation of TDP-43 protein clumps, which contribute to nerve cell…
SOD1-ALS disease progression may slow with RAG-17: Final trial data
An experimental candidate by Ractigen Therapeutics to treat amyotrophic lateral sclerosis (ALS) linked to mutations in the SOD1…